Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, today announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.
The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate Pfizer’s data review processes with artificial intelligence (AI). The result of that initial collaboration was Smart Data Quality (SDQ), which significantly cut down the time to database lock. With this new agreement, Pfizer will continue to scale SDQ to help streamline and accelerate its data review processes across its broader portfolio of global studies.
